Comparative Pharmacology
Head-to-head clinical analysis: MICRO K versus MICRO K LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICRO K versus MICRO K LS.
MICRO-K vs MICRO-K LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium is the principal intracellular cation, essential for maintaining cellular tonicity, electrical neutrality, and enzymatic reactions. It modulates neuromuscular transmission, cardiac contractility, and acid-base balance.
Potassium supplement; replaces intracellular potassium, essential for nerve conduction, muscle contraction, and acid-base balance.
Oral: 20-40 mEq (1-2 capsules) two to four times daily; maximum 100 mEq/day. Each capsule contains 8 mEq (600 mg) of potassium chloride in a wax matrix extended-release formulation.
10-20 mEq (as potassium chloride) orally twice daily; maximum 100 mEq/day.
None Documented
None Documented
Not applicable; potassium is an electrolyte with no true elimination half-life; whole-body turnover half-life is approximately 12-24 hours, clinically relevant for dosing intervals.
Not applicable (K+ is an electrolyte, not eliminated by first-order kinetics). Clinical context: Serum K+ decline follows redistribution and excretion with a half-life of ~2-4 hours after IV bolus.
Renal: approximately 90% of absorbed potassium is excreted in urine; biliary/fecal: less than 10% eliminated via feces.
Renal: ~90% as KCl (proportional to intake). Biliary/fecal: <10%.
Category C
Category C
Electrolyte Supplement (Potassium)
Electrolyte Supplement (Potassium)